Announced Mon, 16 Feb · 16:59 IST

Outcome Of Extra Ordinary General Meeting of the Company.

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Fredun Pharmaceuticals held an Extra-Ordinary General Meeting on 16th February 2026 via video conferencing, which ran for just 7 minutes (9:00 AM to 9:07 AM). The key business transacted was a special resolution to appoint Ms. Pooja N. Sanghavi (DIN: 11387388) as a Non-Executive Independent Director on the board. The meeting was chaired by Dr. (Mrs.) Daulat Nariman Medhora, Jt. Managing Director, with Managing Director Fredun Medhora also present. Remote e-voting was open from 13th to 15th February 2026, and Ms. Kala Agarwal was appointed as Scrutinizer to submit the voting report within two working days. No questions were raised by shareholders during the meeting.

Likely market impact

This is a routine governance update that adds a new Independent Director to the board, strengthening compliance with SEBI's composition requirements. The outcome is unlikely to cause any material stock price movement, but the final voting results (when published) will confirm shareholder support for the appointment.